I have no major concerns regarding this work. I have only few minor comments: -An improvement in signs and symptoms has been observed also in patients switching from preservative free bimatoprost/timolol to preservative-free tafluprost timolol. Would that mean that preservatives are only minimally affecting the tolerability of fixed combinations especially if they are administered only once a day?
This issue might deserve a comment in the discussion which is rather concise.
-In the discussion the authors speculate that the improvement in signs and symptoms could be due to the different active agents in the two ophthalmic formulations (prostaglandin vs prostamide). I would mention also the difference in the concentration of the two active agents.
-In supplemental table S3 I would report the percentage of patients without symptoms at screening by subdividing the group according to the presence or absence of preservatives in the timolol/bimatoprost formulation as it has been done in table 1 and figure 2.
-In table 1 are reported the baseline number and frequencies of specific signs and symptoms at screening. In supplemental table S3 it is reported the number and frequencies of symptoms-free patients at screening. If I'm interpreting correctly the reported frequencies should be one the reciprocal of the other but apparently the numbers do not match (e.g. Tearing in table 1 is reported in 56 patients at screening while in table S3 is reported that at screening 55 patients are tearing-free. If they rather represent different parameters this should be more clearly explained.
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GENERAL COMMENTS
This is an important research question and an interesting paper. I would recommend some minor changes to improve clarity.
Methods
Page 6, line 34: Were signs and symptom collected and analysed per person or per eye?
Page 7, line 47: This paragraph is a bit confusing. It could be assumed that the use of the word "achieved" implies that you had 90% power to reject the null hypothesis given your statistical methods and results. Are you able to make it clearer that the sample size required was initially calculated on the basis of a t-test using data from the tafluprost switch studies but ultimately used the Wilcoxon test for your primary analysis?
Page 7, line 50: Please cite the study that the estimated mean change was based on. No changes required in response to this statement.
The paper is well written, the methodology clear and the limitations of such a study design well described.
No changes required in response to this statement.
I have no major concerns regarding this work. I have only few minor comments:
An improvement in signs and symptoms has been observed also in patients switching from preservative free bimatoprost/timolol to preservative-free tafluprost timolol. Would that mean that preservatives are only minimally affecting the tolerability of fixed combinations especially if they are administered only once a day? This issue might deserve a comment in the discussion which is rather concise.
The second paragraph of the discussion has been amended to address this.
In the discussion the authors speculate that the improvement in signs and symptoms could be due to the different active agents in the two ophthalmic formulations (prostaglandin vs prostamide). I would mention also the difference in the concentration of the two active agents.
We do not think that the concentrations of bimatoprost and tafluprost should be compared as they are different molecules with different potencies. To note, bimatoprost is available as a 0.03% and 0.01% ophthalmic solution. However, bimatoprost-timolol FDC solution is only available with bimatoprost 0.03%. Therefore, we do not think the different concentrations of bimatoprost should be discussed here as it may cause confusion between the monotherapy and FDC formulations
In supplemental table S3 I would report the percentage of patients without symptoms at screening by subdividing the group according to the presence or absence of preservatives in the timolol/bimatoprost formulation as it has been done in table 1 and figure 2. For the "abnormal" symptoms, described in Table  1 , specific criteria were used at the analysis phase of the results as specified in supplementary Page 7, line 47: This paragraph is a bit confusing. It could be assumed that the use of the word "achieved" implies that you had 90% power to reject the null hypothesis given your statistical methods and results. Are you able to make it clearer that the sample size required was initially calculated on the basis of a t-test using data from the tafluprost switch studies but ultimately used the Wilcoxon test for your primary analysis?
The paragraph has been amended.
Page 7, line 50: Please cite the study that the estimated mean change was based on.
References have been added; other reference numbers have been adjusted accordingly.
Page 8, line 7: How were the missing data from the participants who enrolled but did not
The statistical methods paragraph has been amended and now includes these details. This row has been removed.
For Hyperaemia, it would be more beneficial to include the median and IQR of the Ora Calibra score rather than listing that 100% had it. 
FORMATTING AMENDMENTS (if any)
Required amendments will be listed here; please include these changes in your revised version:
Please ensure images are a minimum of 300dpi and a maximum of 600dpi (resolution). where applicable, trial registration: registry and number (for clinical trials and, if available, for observational studies and systematic reviews)
EudraCT number included in the manuscript.
